Despite Hybio Pharmaceutical's share price surge, its high P...

Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.